Abstract
The study included 73 women with stage III HER2-positive locally advanced breast cancer (BC) which received simultaneous chemoradiotherapy in combination with targeted therapy. Patients were stratified into two groups: in the first group patients in the neoadjuvant received concomitant chemoradiotherapy in combination with trastuzumab, in the second group patients were prescribed no targeted therapy. The therapy with trastuzumab appeared to be the most effective. 3-year survival rate in the first group was 85.5%, 73.3% – in the second group, 5-year survival rate was 73.9% and 40.3% respectively (p<0.05). Herewith, disease-free survival was higher in the trastuzumab group, but the difference did not reach statistical significance. 3-year disease-free survival rate in the first group was 71.4%, 47.6% – in the second group, 5-year disease-free survival was 40.9% and 26.0% respectively (p=0.06). In addition, the study analyzed the influence of radical mastectomy surgery on long-term outcomes, and explored the efficacy of different fractionation regimes. The findings led to the conclusion that the combined chemoradiotherapy in combination with targeted therapy is an effective treatment for patients with the HER2-positive locally advanced BC. Provided that this therapy is not inferior to the comprehensive treatment which includes surgery and can be used as an independent method of treatment without surgery and associated complications.
Highlights
Patients were stratified into two groups: in patients from the first group in the neoadjuvant setting received concomitant chemoradiotherapy in combination with trastuzumab, in the second group patients did not receive no targeted therapy
The findings led to the conclusion that the combined chemoradiotherapy in combination with targeted therapy is an effective treatment for patients with the HER2‐positive locally advanced breast cancer (BC)
Cancer Radiotherapy, 2013, Vol 17, No 3, pp
Summary
В настоящее исследование включены женщины старше 18 лет с установленным диагнозом «местно-распространенный не отечно-инфильтративный HER2‐позитивный РМЖ», первично не леченные. 3‐летняя общая выживаемость в группе с трастузумабом составила 88,5 %, в группе без таргетной терапии – 75,3 %. Оценка безрецидивной выживаемости также показала выигрыш в группе, в схему лечения которой входил трастузумаб. Общая выживаемость в группах с назначением и без назначения трастузумаба. Безрецидивная выживаемость в группах с назначением и без назначения трастузумаба. Безрецидивная выживаемость в группах с разными схемами лучевой терапии в зависимости от выбранного режима. При расчете шансов выживаемости после проведенного лечения в группе, где был назначен ускоренный режим лучевой терапии, отношение шансов составило 1,4, что в 3,8 раз выше (95 %, доверительный интервал 1,4– 10,2), чем при проведении конвенционального облучения (РОД 2 Гр). 3 и 4 представлены общая и безрецидивная выживаемость пациентов в группах с различными режимами фракционирования. Исходные данные по влиянию РМЭ на выживаемость пациентов после проведенного лечения
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
